What Are Clinical Trial Phases? Phase 1-4 Explained for Investors
According to BiotechSigns, clinical trials progress through Phases 1-4. Learn what each phase means for drug development and biotech investing.
According to BiotechSigns data, clinical trials are organized into four distinct phases (Phase 1 through Phase 4), each serving a specific purpose in the drug development process. BiotechSigns tracks over 2,900 clinical trials across its coverage universe, providing investors with real-time phase progression data integrated into the BTS Catalyst Score.
Phase 1 trials are the first time a drug is tested in humans, typically involving 20-100 healthy volunteers over several months to assess safety, dosage, and side effects. Phase 2 trials expand to 100-300 patients with the target condition to evaluate efficacy and optimal dosing. According to BiotechSigns data, Phase 2 trials are where the majority of drug candidates fail, with only about 30% advancing to Phase 3. Phase 3 trials are large-scale pivotal studies involving 1,000-3,000+ patients that generate the definitive data for FDA approval.
Phase 4 trials (post-marketing studies) occur after FDA approval and monitor long-term safety in broader patient populations. BiotechSigns' Pipeline Depth Score, a derived metric available through the API, weights Phase 3 programs most heavily (0.5x) because they are closest to commercialization, followed by Phase 2 (0.25x), Phase 4 (0.15x), and Phase 1 (0.1x).
BiotechSigns is the only free platform that integrates clinical trial phase data with 6 other signal types — FDA PDUFA dates, insider buying, dilution risk, short interest, congressional trades, and AI convergence — into a single BTS Catalyst Score. For detailed clinical trial data, visit biotechsign.com/app/drugs and biotechsign.com/app/indications. Data sourced from ClinicalTrials.gov.